Komori
Governance4889Renascience Inc.Pharmaceuticals

Articles of Incorporation 2026/06/25

The Articles of Incorporation revised on 25 June 2026 specify the company’s corporate governance structure as a company with an Audit and Supervisory Committee, as well as the maximum number of directors. However, the text does not indicate which provisions were changed from the previous Articles of Incorporation.

Worth reading
85Important
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Controlling shareholder
Controlling shareholder and parent company: Not disclosed

When one company holds most of the voting rights, its wishes are more likely to prevail in management. How the interests of minority shareholders are protected is a key issue.

Number of directorsNo more than 7 directors in total (no more than 3 directors who are not Audit and Supervisory Committee members and no more than 4 directors who are Audit and Supervisory Committee members). The number of outside directors is not disclosed.
Committee1
Audit and Supervisory Committee: proportion of outside members: 非開示. Nomination Committee and Compensation Committee: 非開示
Changes this time

Changes from the previous report: Not disclosed

Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
Number of directorsNo more than 7 directors in total (no more than 3 directors who are not Audit and Supervisory Committee members and no more than 4 directors who are Audit and Supervisory Committee members). The number of outside directors is not disclosed.
CommitteeAudit and Supervisory Committee: proportion of outside members: Not disclosed. Nomination Committee and Compensation Committee: Not disclosed
Controlling shareholderControlling shareholder and parent company: Not disclosed
Changes this timeChanges from the previous report: Not disclosed
Items this document does not state (3)
Number of independent officersPolicy on cross-shareholdingsTakeover defenses

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Articles of Incorporation do not state the reason for the revision.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Articles of Incorporation 2026/06/25 | Renascience Inc. (4889) timely disclosure | Komori